Related references
Note: Only part of the references are listed.Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura
Lucas Kuehne et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)
Mind and matter: The neurological complications of thrombotic thrombocytopenic purpura
Rebecca J. Shaw et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study
Marie Scully et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)
Redefining outcomes in immune TTP: an international working group consensus report
Adam Cuker et al.
BLOOD (2021)
Real-world experience with caplacizumab in the management of acute TTP
Tina Dutt et al.
BLOOD (2021)
Multimer Analysis of Von Willebrand Factor in Von Willebrand Disease with a Hydrasys Semi-Automatic Analyzer-Single-Center Experience
Ingrid Skornova et al.
DIAGNOSTICS (2021)
Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19
Peter L. Turecek et al.
THROMBOSIS RESEARCH (2021)
Histone-induced thrombotic thrombocytopenic purpura in adamts13-/- zebrafish depends on von Willebrand factor
Liang Zheng et al.
HAEMATOLOGICA (2020)
Anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura do not hamper ELISA-based quantification of ADAMTS13 antigen
Charlotte Dekimpe et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study
Paul Knoebl et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Linus A. Voelker et al.
BLOOD ADVANCES (2020)
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura
X. Long Zheng et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Antibodies that conformationally activate ADAMTS13 allosterically enhance metalloprotease domain function
An-Sofie Schelpe et al.
BLOOD ADVANCES (2020)
Comparison of the Long-Term Remission of Rituximab and Conventional Treatment for Acquired Thrombotic Thrombocytopenic Purpura: A Systematic Review and Meta-Analysis
Weerapat Owattanapanich et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2019)
How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns
Marshall A. Mazepa et al.
BLOOD (2019)
Semi-automated von Willebrand factor multimer assay for von Willebrand disease: Further validation, benefits and limitations
Susan Oliver et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2019)
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
M. Scully et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine
Paul Coppo et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2019)
Preclinical evaluation of a semi-automated and rapid commercial electrophoresis assay for von Willebrand factor multimers
Marika Pikta et al.
JOURNAL OF CLINICAL LABORATORY ANALYSIS (2018)
An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura
E. Roose et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura
Matthieu Jestin et al.
BLOOD (2018)
Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab
Tanja Falter et al.
THROMBOSIS AND HAEMOSTASIS (2018)
Evaluation of a semi-automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European Centers
Annette E. Bowyer et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2018)
Thrombotic thrombocytopenic purpura
Johanna A. Kremer Hovinga et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura
Wenjing Cao et al.
HAEMATOLOGICA (2016)
Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura
Wenjing Cao et al.
HAEMATOLOGICA (2016)
Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTS-13
L. Deforche et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH
I. Bodo et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura
Miguel Hie et al.
BLOOD (2014)
Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies
Tobias A. Fuchs et al.
BLOOD (2012)
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
Marie Scully et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center
Antoine Froissart et al.
CRITICAL CARE MEDICINE (2012)
Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura
Rahel Froehlich-Zahnd et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura
Marie Scully et al.
BLOOD (2011)
Survival and relapse in patients with thrombotic thrombocytopenic purpura
Johanna A. Kremer Hovinga et al.
BLOOD (2010)
Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus)
Hendrik B. Feys et al.
BLOOD (2010)
Thrombotic-thrombocytopenic purpura
M. Hellmann et al.
INTERNIST (2010)
The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis
Anil K. Chauhan et al.
BLOOD (2008)
Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse
Ming Jin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission
Flora Peyvandi et al.
HAEMATOLOGICA (2008)
Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay:: comparison with other assay methods
JAK Hovinga et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay
K Kokame et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow
A Bernardo et al.
BLOOD (2004)
ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions
JF Dong et al.
BLOOD (2002)
Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases
A Veyradier et al.
BLOOD (2001)
Share Paper
